Podcasts about Idiopathic pulmonary fibrosis

MaryLuz Fuentes, MD, a former clinician and double-lung transplant survivor will typically say this to other IPF patients: "We patients may be short of breath, but not short of hope." On this episode with host Patti Tripathi, Dr. Fuentes talks about what led up to her double-lung transplant three years ago and what's in store for her at the ATS 2025 International Conference in May. 

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Le Xu, Ph.D., examines the intricate processes underlying lung development and disease, with a focus on idiopathic pulmonary fibrosis (IPF). Xu explores the roles of genetic and cellular mechanisms, including the hedgehog pathway, FGF signaling, and epithelial-mesenchymal interactions, in driving lung fibrosis. Xu also highlights links between congenital diaphragmatic hernia (CDH) and lung development, suggesting that both mechanical and genetic factors contribute to lung hypoplasia. The discussion includes the development of advanced mouse models that replicate key aspects of human IPF, offering insights into fibrosis progression. Xu's research ultimately seeks to identify the causes of lung tissue abnormalities and pave the way for targeted therapies. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39460]

Our episode today is diving into a broader initiative to discuss the management of interstitial lung disease. In this episode we will be talking about the treatment of Idiopathic Pulmonary Fibrosis through the lens of a journal club discussion of … Continue reading →

Today's guest is Terri Pilawa. Terri started feeling ill in 2008 and was finally diagnosed correctly after 4 years of not knowing what was wrong in 2012 with Idiopathic Pulmonary Fibrosis. She was told she needed a lung transplant. In 2015, she had a successful double lung transplant. As a part of her journey she became involved with the One Breath Foundation and is now the CEO. Let's hear about both her IPF journey and her involvement in the One Breath Foundation.

Idiopathic Pulmonary Fibrosis (IPF) is a devastating lung disease affecting millions worldwide, with a grim prognosis of only three to five years post-diagnosis. In this episode, leading lung disease expert Victor Thannickal, MD, delves into the symptoms, progression, and impacts of IPF. He also sheds light on promising new drug therapies emerging from his lab, offering hope in the fight against this relentless disease. Host Elaine Hamm, PhD, skillfully navigates the complex landscape of IPF, making this a must-listen for anyone interested in cutting-edge biotech developments. If you enjoyed the episode, please consider liking, sharing, and subscribing to BIO from the BAYOU. Your support helps us continue delivering high-quality content to listeners passionate about the biotech industry.

Host: Jonathan Chung, MD Host: Seth Kligerman, MD Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach.

CME credits: 1.00 Valid until: 07-11-2024 Claim your CME credit at https://reachmd.com/programs/clinicians-roundtable/idiopathic-pulmonary-fibrosis-the-role-of-radiology-in-accurate-and-timely-diagnosis/18077/ Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology in effectively diagnosing IPF with a multidisciplinary team approach. =

Dr. Sunad Rangarajan chats with Dr. Corrine Kliment about her article, "Loss of ANT1 Increases Fibrosis and Epithelial Cell Senescence in Idiopathic Pulmonary Fibrosis." 

Join us on a remarkable journey with Alastair Henry, the adventurous boomer and double lung transplant survivor who turned his life around post-retirement. From the corporate boardrooms to the remote Canadian North, to volunteering across the globe, Alastair's story is a testament to living life to the fullest. Discover how he embraced indigenous wisdom, tackled idiopathic pulmonary fibrosis, and found joy in simplicity on this inspiring episode of the Living the Dream podcast with Curveball.

Dr. Mohleen Kang chats with Dr. Aparna Swaminathan and Dr. Timothy Dempsey about their articles, "External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources” and “The Added Power of Synthetic Control Groups: Challenging Conventional Wisdom and Trial Design in Idiopathic Pulmonary Fibrosis Research.” 

The publication of this podcast was funded by CSL Behring. The views and opinions expressed are exclusively those of the speakers.   In this section, the panel considers the expert insights of Prof. Wijsenbeek, concerning the challenges of predicting the disease course and prognosis of patients with idiopathic pulmonary fibrosis (IPF). The conversation reflects on current knowledge, real-world practices, treatment options, and tools available to healthcare professionals.

The publication of this podcast was funded by CSL Behring. The views and opinions expressed are exclusively those of the speakers. In this section, the panel considers the diagnostic tools and approaches available for healthcare professionals to use for suspected idiopathic pulmonary fibrosis (IPF). The discussion is directed towards the expertise of Prof. Luca Richeldi, who emphasises the importance of knowledge, education, and medical examination approaches for addressing the unmet medical needs associated with the awareness of, and diagnostic delays of IPF.

Idiopathic Pulmonary Fibrosis, or IPF, is a progressive lung disease with genetic and environmental causes, affecting 5 million people globally. Although pollutants have long been linked to a range of lung diseases,  no conclusive evidence regarding their link to IPF has been sought thus far. The research of Dr. Eun Joo Kim, a post-doctorate researcher at The University of Colorado Anschutz Medical Campus, defines the role of cilia in lung repair following injury, and details how cilia related genes may be responsible for the severity of symptoms.Read the original article: https://doi.org/10.1165/rcmb.2021-0554OC

Ben Verlander welcomes New York Yankees legend Bernie Williams back to the show. They discuss the current state of the New York Yankees, what it meant to have his number retired and what advice he would give Shohei Ohtani during free agency. They also talk about his favorite Derek Jeter story, what he sees in Yankees' Jasson Dominguez and his thoughts on New York Mets new manager Carlos Mendoza. Bernie also talks about National Caregivers Month, his father's battle with Idiopathic Pulmonary Fibrosis (or IPF) and his work with Boehringer Ingleheim & the Tune In To Lung Health Program. Learn more about your ad choices. Visit megaphone.fm/adchoices

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.08.02.551383v1?rss=1 Authors: Cohen, M. L., Brumwell, A. N., Ho, T. C., Montas, G., Golden, J. A., Jones, K. D., Wolters, P. J., Wei, Y., Chapman, H. A., Le Saux, C. J. Abstract: Reciprocal interactions between alveolar fibroblasts and epithelial cells are crucial for lung homeostasis, injury repair, and fibrogenesis, but underlying mechanisms remain unclear. To investigate this, we administered the fibroblast-selective TGF{beta}1 signaling inhibitor, epigallocatechin gallate (EGCG), to Interstitial Lung Disease (ILD) patients undergoing diagnostic lung biopsy and conducted single-cell RNA sequencing on spare tissue. Unexposed biopsy samples showed higher fibroblast TGF{beta}1 signaling compared to non-disease donor or end-stage ILD tissues. In vivo, EGCG significantly downregulated TGF{beta}1 signaling and several pro-inflammatory and stress pathways in biopsy samples. Notably, EGCG reduced fibroblast secreted Frizzle-like Receptor Protein 2 (sFRP2), an unrecognized TGF{beta}1 fibroblast target gene induced near type II alveolar epithelial cells (AEC2s). In human AEC2-fibroblast coculture organoids, sFRP2 was essential for AEC2 trans-differentiation to basal cells. Precision cut lung slices (PCLS) from normal donors demonstrated that TGF{beta}1 promoted KRT17 expression and AEC2 morphological change, while sFRP2 was necessary for KRT5 expression in AEC2-derived basaloid cells. Wnt-receptor Frizzled 5 (Fzd5) expression and downstream calcineurin-related signaling in AEC2s were required for sFRP2-induced KRT5 expression. These findings highlight stage-specific TGF{beta}1 signaling in ILD, the therapeutic potential of EGCG in reducing IPF-related transcriptional changes, and identify the TGF{beta}1-non-canonical Wnt pathway crosstalk via sFRP2 as a novel mechanism for dysfunctional epithelial signaling in Idiopathic Pulmonary Fibrosis/ILD. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

In this podcast, Drs Jeffrey Swigris and Toby Maher discuss the future of idiopathic pulmonary fibrosis. Find out where we're headed regarding diagnostic and treatment innovations on the near horizon. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982426). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Idiopathic Pulmonary Fibrosis: Present Understanding and Future Options https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584113/ Predicting Prognosis in Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/21319590/ Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/35569036/ Inhaled Treprostinil and Forced Vital Capacity in Patients With Interstitial Lung Disease and Associated Pulmonary Hypertension: A Post-hoc Analysis of the INCREASE Study https://pubmed.ncbi.nlm.nih.gov/34214475/ Pulmonary Fibrosis Foundation https://www.pulmonaryfibrosis.org/ Predictors of Progression in Systemic Sclerosis Patients With Interstitial Lung Disease https://pubmed.ncbi.nlm.nih.gov/32079645/

In this special episode Liz tells us about her experience of living with RA-ILD, which is short for rheumatoid arthritis-associated interstitial lung disease. We explore the profound impact of this life-changing diagnosis on Liz and her loved ones as well as the need for increased awareness of the condition. Throughout Liz provides advice and strategies for maintaining a positive outlook despite the challenges RA-ILD presents.

This episode covers interstitial lung disease, including idiopathic pulmonary fibrosis.Written notes can be found at https://zerotofinals.com/medicine/respiratory/interstitiallungdisease/ or in the respiratory section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.

Dr Jeffrey J. Swigris and Professor Anne Holland discuss the finer points of oxygen therapy for patients with idiopathic pulmonary fibrosis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982425). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Home Oxygen Therapy for Adults With Chronic Lung Disease: An Official ATS Clinical Practice Guideline Implementation Tools https://www.thoracic.org/statements/guideline-implementation-tools/home-oxygen-therapy-for-adults.php The King's Brief Interstitial Lung Disease (KBILD) Questionnaire: An Updated Minimal Clinically Important Difference https://bmjopenrespres.bmj.com/content/6/1/e000363 Ambulatory Oxygen for Treatment of Exertional Hypoxaemia in Pulmonary Fibrosis (PFOX Trial): A Randomised Controlled Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737108/

In this episode, we explore how innovating today could have a positive impact on those diagnosed with pulmonary fibrosis. We are joined by extraordinary guests, including researchers, healthcare providers, innovators, and a patient impacted by this rare disease. Keeping patients' lived experiences front and center can help lead to new ideas and progress, all while inspiring us to remain hopeful for the future.

Editor's Summary by Anne Rentoumis Cappola, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the May 9, 2023, issue. Related Content: Audio Highlights

KSQD 5-06-2023: Advances in anti-aging drugs; A survey of many brain-computer interface devices available and being developed

Drs Jeffrey Swigris and Marlies Wijsenbeek discuss how to best manage care for patients with idiopathic pulmonary fibrosis using remote monitoring to address quality-of-life concerns. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982423). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Remote Monitoring in Idiopathic Pulmonary Fibrosis: Home Is Where the Bluetooth-Enabled Spirometer Is https://www.atsjournals.org/doi/full/10.1164/rccm.202005-1532ED Challenges in Pulmonary Fibrosis – 1: Use of High Resolution CT Scanning of the Lung for the Evaluation of Patients With Idiopathic Interstitial Pneumonias https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117220/ Spirometry: Step by Step https://breathe.ersjournals.com/content/8/3/232

Drs Jeffrey Swigris and Ayodeji Adegunsoye discuss fibrosing interstitial lung disease and treatment challenges for individuals with idiopathic pulmonary fibrosis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982422). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Idiopathic Pulmonary Fibrosis (An Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline https://pubmed.ncbi.nlm.nih.gov/35486072/ Health-Related Quality of Life and Symptoms in Patients With IPF Treated With Nintedanib: Analyses of Patient-Reported Outcomes From the INPULSIS® Trials https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990488/ Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Clinical Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089322/

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease that leads to progressive lung scaring and eventual respiratory failure; it most often affects the elderly. The American Thoracic Society and other international bodies updated clinical practice guidelines for this disease in 2022. Tracy Luckhardt, MD, a pulmonologist, summarizes the most important changes to diagnosis, pharmacological treatments, and non-pharmacological treatments. Learn more about the advantages of an interdisciplinary team in managing symptoms and comorbidities of IPF, including determining when a patient is a good candidate for clinical trials or a lung transplant.

Eric LeFebvre, MD, Chief Medical Officer at Pliant Therapeutics, discusses positive safety and efficacy data from the phase 2a INTEGRIS-IPF clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF).IPF is a chronic, progressive, fibrosing lung disease with few treatment options and a poor prognosis. Common symptoms of IPF include shortness of breath and difficulty performing daily activities, such as walking and talking. Currently, there is no pharmacological cure for IPF with neither of the approved two therapies demonstrating an ability to stop the progression of the disease.

Idiopathic pulmonary fibrosis (IPF) is one of the common forms of interstitial lung disease (those that affect the tissues between airways); it results in scarring and fibroblasts. Early diagnosis is critical to the management of this dangerous condition. Carla Copeland, MD, explains the challenge of diagnosing IPF due to its generic symptoms, which usually indicate more common breathing issues. She discusses recent innovations in how CT scans are categorized to better diagnose IPF and to help recommend patients for biopsies. Learn why Dr. Copeland works with a multidisciplinary discussion team (MDT) to diagnose this condition accurately and to begin treatment as soon as possible.

In the fifth and final episode of season 3, we learn about the impact that pulmonary fibrosis can have on relationships with family and friends, and even on the more intimate aspects of partner relationships. Our contributors also take time to emphasize the value that they derive from healthy and supportive relationships when living with this challenging condition.

2.12 Idiopathic Pulmonary Fibrosis   Pulmonary system review for the USMLE Step 1 exam.

In the second episode of Season 3 of our Journey Through Pulmonary Fibrosis podcast, we are once again joined by several people who live with the condition, including a wife and care partner, and by a group of specialists. Hear about some of the challenges that people with pulmonary fibrosis face in terms of meeting their dietary and nutritional needs and learn about how these challenges are best managed through tools and techniques like keeping a food diary and managing portion sizes.

What is an acute exacerbation? Are there different types of exacerbation related to Idiopathic Pulmonary Fibrosis? Dr. Nathaniel Marchetti of Temple Lung Center joins host Kevin Crockett to discuss acute exacerbation and more! Brought to you by the Wescoe Foundation for Pulmonary Fibrosis and the Pennsylvania IPF Support Network!! Find the 'PULMONARY FIBROSIS' podcast on Google, Spotify, Apple podcasts - wherever you get your podcasts - or at PAIPFSupportNetwork.org!!See omnystudio.com/listener for privacy information.

In the first episode of Season 3, we are joined by a courageous group of guests that includes people living with pulmonary fibrosis, a care partner, and specialized healthcare providers to explore the mental health impact of the disease. The discussion explores the impact of receiving a pulmonary fibrosis diagnosis and the ongoing challenges of living with the disease. Our guests share the mental and emotional challenges they face, as well as helpful tips on how to cope, where to find support and how they continue to find hope.

Idiopathic Pulmonary Fibrosis with Dr Horne by Dr. Laura Caputo

Moderators Aravind M Menon, MD, MPH, and Alice Gallo de Moraes, MD, and journal CHEST® author Sahajal Dhooria, MD, DM, discuss the article, "MUC5B Promoter Polymorphism and Survival in Indian Patients With Idiopathic Pulmonary Fibrosis," which was published in the October issue. DOI: https://doi.org/10.1016/j.chest.2022.04.001

Today's Episode Dr. Raj and Dr. Eva Khondaker review the case of a 68 year old man who presents to the outpatient clinic after 6 months of progressive exertional dyspnea and a persistent dry cough. He has a 15 pack year history of smoking but quit 20 years ago, and he has no family history of lung disease. Today's Guest Dr. Eva Khondaker is a recent medical graduate from the University of Medicine and Health Sciences (UMHS) where she graduated with highest honors. She holds a Bachelor of Science Degree from the University of Alberta majoring in Biological Sciences and a Minor in Classics. Eva has over 10 years of media and broadcasting experience. Her experience ranges from appearing in local news channels to International Tv networks such as ATN (Asian television network). Eva was crowned Miss Canada Galaxy International 2007, Miss Alberta 2007 and Miss Supermodel South Asia 2006. She also went on to represent Canada at an International platform and placed 1st runner up and awarded best in swimsuit and interview. She was also awarded 1st runner up in Miss India Canada 2007 in Toronto, Ontario. In the past, Eva has been an ambassador for various charity organization such as the Canadian Red cross and the Cross cancer institute to name a few. She has helped raise awareness and funding for research. Eva is also a published co-author of a Medical Ethics and Biostatistics textbook specifically for students preparing for the USMLE exams. Recently, Eva has joined inside the boards as a podcast host, tutor, question writer, and head of social media development. In her personal life, she is a trained kathak and bharatnatyam dancer (Classical East Indian dance). She loves going to the gym and all things scifi/fantasy related. In her spare time she enjoys spending time with her dog son, Quincy! She loves to go for hikes and play fetch with Quincy. She is currently preparing for the 2023 Match cycle. About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. More from Dr. Raj www.BeyondThePearls.net The Dr. Raj Podcast Dr. Raj on Twitter Dr. Raj on Instagram Want more board review content? Crush Step 1 Step 2 Secrets Physiology by Physeo Step 1 Success Stories The InsideTheBoards Study Smarter Podcast The InsideTheBoards Podcast Study on the go for free! Download the Audio QBank by InsideTheBoards for free on iOS or Android. If you want to upgrade, you can save money on a premium subscription by customizing your plan until your test date on our website! Produced by Ars Longa Media To learn more about us and this podcast, visit arslonga.media. You can leave feedback or suggestions at arslonga.media/contact or by emailing info@arslonga.media. Produced by: Christopher Breitigan Executive Producer: Patrick C. Beeman, MD Legal Stuff InsideTheBoards is not affiliated with the NBME, USMLE, COMLEX, or any professional licensing body. InsideTheBoards and its partners fully adhere to the policies on irregular conduct outlined by the aforementioned credentialing bodies. The information presented in this podcast is intended for educational purposes only and should not be construed as professional or medical advice. Learn more about your ad choices. Visit megaphone.fm/adchoices

Are you or someone you know living with Idiopathic Pulmonary Fibrosis?! We have got a GREAT episode this time around with excellent information on the patient and caregiver experience from a patient living with IPF. Jim Carns joins Crockett to tell us about the patient experience of living with IPF, and about lung transplants. It's the 'PULMONARY FIBROSIS' podcast! Brought to you by the Wescoe Foundation for Pulmonary Fibrosis, and the PAIPF Support Network! Learn more at PAIPFSUPPORTNETWORK.org!!See omnystudio.com/listener for privacy information.

By way of an exquisite toggling of activity, HADUVIO stimulates one opioid receptor (kappa) and blocks the activity of another (mu) while avoiding the engagement of the third (delta). The objective of this combination of receptor activity is to decrease chronic cough due to Idiopathic Pulmonary Fibrosis, or severe itch due to Prurigo Nodularis. Phase II data are available for both development programs, which CEO Jennifer Good has proudly shared—along with a story of how Trevi got its name…

How does dapagliflozin affect kidney outcomes in patients hospitalized with COVID-19? Find out about this and more in today's PV Roundup podcast.

What a first year it has been! We've gotten to know SO MUCH about Idiopathic Pulmonary Fibrosis, and this whole idea for an informational podcast started with Jen Wescoe of the Wescoe Foundation for Pulmonary Fibrosis! She tells us about what exciting things we can expect from the show in 2022 in this episode of the PULMONARY FIBROSIS PODCAST! Brought to you by the the Pennsylvania IPF Support Network and the Wescoe Foundation for Pulmonary Fibrosis! Find the 'Pulmonary Fibrosis' podcast on Spotify, Apple Podcasts or wherever you get your podcasts - and learn more at paipfsupportnetwork.org!!See omnystudio.com/listener for privacy information.

When it comes to facing a diagnosis of Pulmonary Fibrosis, it takes a TEAM to communicate and work together to make this life transition as smooth as possible. What are the Palliative Care benefits for Idiopathic Pulmonary Fibrosis? We take a deep dive in the ‘PULMONARY FIBROSIS’ podcast!! Crockett is joined by the PA Pulmonary Fibrosis Support Network and Dr. Patricia Fogelman, the System Director of Palliative Medicine with the Guthrie Clinic, to discuss the benefits of palliative care. Find the ‘PULMONARY FIBROSIS’ podcast wherever you get your podcasts – and learn more at paipfsupportnetwork.org!See omnystudio.com/listener for privacy information.

Aging-US published "A model of the aged lung epithelium in idiopathic pulmonary fibrosis" which reported that Iiopathic pulmonary fibrosis (IPF) is an age-related disorder that carries a universally poor prognosis. By exposing mouse alveolar epithelial cells to repeated, low doses of bleomycin, instead of usual one-time exposures, the authors uncovered changes strikingly similar to those in the IPF lung epithelium. They propose that this simple yet powerful tool could help uncover new biological mechanisms and assist in developing new pharmacological tools to treat the disease. Dr. Ross Summer from The Jane and Leonard Korman Respiratory Institute as well as Dr. Freddy Romero from The Baylor College of Medicine said, "Idiopathic pulmonary fibrosis (IPF) represents one of the most aggressive and irreversible lung diseases, has an unknown etiology, and limited therapeutic options." IPF arises from low-grade insults to the alveolar epithelium, which exhaust stem cell capacity and activate pathways that result in progressive tissue remodeling. Age represents the most significant risk factor for the development of IPF. Senescent cells are believed to drive immune cell and fibroblast activation via their production of secretory proteins (SASP), such as IL-6, TNF-β and TGF-β. Emerging evidence indicates that experimentally-induced pulmonary fibrosis can be ameliorated by targeting senescent cells for destruction [15]. This suggests a role for senolytic therapies in the treatment of IPf. The Summer/Romero Research Team concluded in their Aging-US Research Output, "we describe a novel model of the IPF lung epithelium that displays many characteristics of the dysfunctional IPF alveolar epithelium. Given its low cost and ease of implementation, we believe our model is ideally suited for uncovering the molecular underpinnings driving mitochondrial dysfunction, cellular senescence and loss of proteostasis in IPF. Further, we believe our model is also ideally suited for high throughput testing of novel pharmacological compounds directed at the alveolar epithelium. This includes drugs aimed at eliminating dysfunction epithelial cells, such as senolytic medications and agents that aim to restore health to the IPF alveolar epithelium" DOI - https://doi.org/10.18632/aging.203291 Full Text - https://www.aging-us.com/article/203291/text Correspondence to: Ross Summer email: Ross.Summer@Jefferson.edu and Freddy Romero email: Freddy.RomeroVasquez@bcm.edu Keywords: aging, IPF, mitochondria, proteostasis, epithelial cells About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research as well as topics beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, cancer, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR among others), and approaches to modulating these signaling pathways. To learn more about Aging-US, please visit http://www.Aging-US.com or connect with @AgingJrnl Aging-US is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact 18009220957x105 MEDIA@IMPACTJOURNALS.COM

The battle against Idiopathic Pulmonary Fibrosis continues!! Dr. Daniel Kass, an Associate Professor of Medicine at the University of Pittsburgh and the Director of the Dorothy P. & Richard P. Simmons Center for ILD, joins host Kevin Crockett to discuss managing the symptoms of IPF, and how the Pennsylvania IPF Support Network is helping to take on the disease! Check out episode THREE of the PULMONARY FIBROSIS PODCAST! Visit: https://paipfsupportnetwork.org/ for more information! Kindly like/subscribe/download/review wherever you get your podcasts!See omnystudio.com/listener for privacy information.

The passion to fight Idiopathic Pulmonary Fibrosis is STRONG in Dr. Rebecca Bascom!! Dr. Bascom, from Penn State Medical Center of Hershey, joins host Kevin Crockett to discuss IPF treatments, and what the Pennsylvania IPF Support Network is doing to help fight his disease! It's episode two of the PULMONARY FIBROSIS PODCAST! Visit: https://paipfsupportnetwork.org/ for more information! Kindly like/subscribe/download/review wherever you get your podcasts!See omnystudio.com/listener for privacy information.

We are joined by John who spent a decade seeking a correct diagnosis of the rare lung disease, Idiopathic Pulmonary Fibrosis. Listen to him explain the importance of sharing symptoms with your doctor and how he considers his eventual diagnosis to be the beginning of a new journey.

In a special episode on COVID-19 and the effect on the pulmonary fibrosis community, we are joined by Bill Vick, Founder of PF Warriors, and pulmonologist Dr. Leticia Kawano-Dourado. Listen to them share their experiences of the pandemic and discuss how those living with pulmonary fibrosis can best protect themselves during these uncertain times.

In the first episode of the series we are joined by special guest Dr Craig Conoscenti, medical expert in interstitial lung disease on the clinical development and medical affairs team at Boehringer Ingelheim. Listen to him discuss his experiences as both physician and caregiver to his own father, and the importance of creating a positive patient journey.

In this episode I cover interstitial lung disease.If you want to follow along with written notes on interstitial lung disease go to https://zerotofinals.com/interstitiallungdisease/ or find the respiratory section in the Zero to Finals medicine book.This episode covers idiopathic pulmonary fibrosis, drug induced pulmonary fibrosis, secondary pulmonary fibrosis, hypersensitivity pneumonitis (AKA extrinsic allergic alveolitis), cryptogenic organising pneumonia and asbestosis.The audio in the episode was expertly edited by Harry Watchman.